What testing does SaiyanMed perform on each batch?

Every batch of peptides from saiyanmed undergoes a multi-layered testing protocol designed to catch impurities, confirm identity, and verify purity down to the decimal. The core of this process is independent third-party analysis by Janoshik Analytical, a lab widely recognized in the research peptide community for its rigorous methodology and transparent reporting. SaiyanMed does not rely on in-house testing alone—they send samples from each batch to Janoshik for HPLC (High-Performance Liquid Chromatography) and mass spectrometry (MS) analysis. HPLC measures purity by separating compounds in the sample, giving a percentage that reflects how much of the material is the target peptide versus any residual solvents, truncated sequences, or other byproducts. Mass spectrometry confirms the molecular weight of the peptide, ensuring the compound matches the expected structure. For example, a typical batch of BPC-157 might show a purity of 99.2% or higher, with MS confirming the exact mass of 1419.6 Da. These reports are published openly on the SaiyanMed website, with a unique batch number that lets you cross-reference the data directly with Janoshik’s database. This is not a one-time check—every single production batch gets its own report, so you can see the variation between batches and verify consistency over time.

Beyond the third-party analysis, SaiyanMed performs in-process quality control at multiple stages of production. The raw materials are sourced from GMP-compliant facilities, and each incoming lot of peptide powder is tested for endotoxin levels using the LAL (Limulus Amebocyte Lysate) test, which detects bacterial endotoxins that could interfere with research results. The acceptable threshold is less than 1 EU/mg, a standard that aligns with pharmaceutical-grade requirements. After lyophilization—the freeze-drying process that turns the peptide into a stable powder—the final product is checked for moisture content using Karl Fischer titration. Moisture levels above 5% can degrade the peptide over time, so SaiyanMed targets below 3% for most products. They also test for pH after reconstitution in a standard solvent like bacteriostatic water, ensuring the solution falls within a range that supports peptide stability (typically pH 4.5–6.5). These parameters are documented in the Certificate of Analysis (CoA) that accompanies each batch, which includes the testing date, method, and results for purity, identity, moisture, and endotoxins.

To give you a concrete picture, here’s a sample testing profile from a recent batch of Semaglutide (a common research peptide):

Parameter	Method	Result	Specification
Purity (HPLC)	Reverse-phase HPLC	99.4%	≥98.0%
Identity (MS)	ESI-MS	4113.8 Da	4113.6–4114.0 Da
Endotoxin (LAL)	Kinetic turbidimetric	0.05 EU/mg	<1.0 EU/mg
Moisture (Karl Fischer)	Volumetric titration	2.1%	<3.0%
pH (reconstituted)	pH meter	5.2	4.5–6.5

This level of detail is not typical in the research peptide market. Many suppliers offer only a single HPLC trace or a generic CoA that doesn’t specify the batch number or testing lab. SaiyanMed’s approach is different: they publish the raw data from Janoshik, including the chromatogram and mass spectrum, so you can visually inspect the peak shape and confirm there are no significant impurities. For instance, a clean HPLC chromatogram will show a single dominant peak with no shoulders or secondary peaks, indicating that the peptide is not contaminated with truncated fragments or oxidized variants. The mass spectrum will show a clear molecular ion peak, with no extra peaks that would suggest a different compound. This transparency is a direct response to the industry’s history of adulterated or mislabeled products—cases where a vial labeled as “Tirzepatide” actually contained something else entirely. By making the testing data verifiable, SaiyanMed gives researchers the confidence to trust the material in their experiments.

The testing frequency is also worth noting. SaiyanMed tests every batch, not just random samples. This means that if you order a vial from a batch with a specific lot number, you can look up the CoA for that exact lot. The batch numbers are printed on the vial labels, and the reports are archived on the website with a search function. This is a significant operational commitment—testing costs money, and for a company that produces multiple peptides in various quantities, the expense adds up. But SaiyanMed treats it as non-negotiable, because the alternative—skipping tests or using pooled samples—would introduce uncertainty. In a research context, where a 1% difference in purity can affect dose-response curves or binding assays, that uncertainty is unacceptable. The company also maintains a retained sample library, where a portion of each batch is stored under controlled conditions for at least 12 months. This allows for re-testing if a researcher reports an anomaly or if a new analytical method becomes available.

Another layer is the stability testing that SaiyanMed conducts on select batches. Peptides are inherently fragile—they can degrade due to temperature fluctuations, light exposure, or even the type of vial used. SaiyanMed performs accelerated stability studies by storing samples at 40°C and 75% relative humidity for 30 days, then re-testing them for purity and moisture. This simulates the stress of shipping and storage, and the results help determine the recommended shelf life. For example, a batch of Melanotan II might show a purity drop from 99.0% to 98.5% after 30 days at elevated temperature, which is within acceptable limits. The data from these studies are not always published on the CoA, but they are available upon request, and they inform the company’s packaging decisions—such as using amber glass vials to block UV light and including desiccant packs in the shipping containers.

Then there’s the personnel training aspect. The testing is only as good as the people who run it. SaiyanMed’s production and quality control teams are trained in GMP principles, and they follow standard operating procedures (SOPs) for every step, from weighing raw materials to sealing vials. The SOPs cover things like how to handle the peptide powder to avoid cross-contamination, how to calibrate the HPLC equipment, and how to interpret the results. The company also participates in inter-laboratory comparisons, where they send samples to multiple labs (including Janoshik and another independent lab) to cross-validate the results. This catches any systematic errors in their own testing methods. For instance, if one lab reports a purity of 99.2% and another reports 98.8%, the discrepancy is investigated. These comparisons are done quarterly, and the findings are used to refine the testing protocols.

Let’s talk about the raw material sourcing because it’s directly tied to the testing results. SaiyanMed sources peptide raw materials from manufacturers that are ISO 9001 certified and have a track record of supplying to pharmaceutical companies. Each incoming raw material batch is tested for identity and purity before it’s used in production. This pre-screening reduces the risk of starting with a substandard material. The raw materials are stored in a temperature-controlled environment (2–8°C for most peptides) to prevent degradation before processing. The company also uses argon gas flushing in the vials during packaging to displace oxygen, which can oxidize peptides over time. This is a detail that many suppliers overlook, but it makes a measurable difference in long-term stability. The testing data from Janoshik often includes a note about the storage conditions, so you can see that the sample was handled properly before analysis.

The lyophilization process itself is another point of quality control. SaiyanMed uses a programmable freeze-dryer that controls the temperature ramp and vacuum pressure to produce a consistent cake structure. A poorly lyophilized peptide can look like a cracked or collapsed powder, which indicates that the process was too aggressive or too slow. The company’s SOP specifies a primary drying temperature of -20°C and a secondary drying temperature of 25°C, with a vacuum level of 0.1 mbar. After lyophilization, the vials are sealed under vacuum or nitrogen, and the seal integrity is checked by visual inspection and leak testing using a dye bath. Any vials with cracks or incomplete seals are discarded. This attention to the physical form of the peptide is important because a broken cake can have a larger surface area, which might accelerate degradation when exposed to moisture.

For researchers who want to dive deeper, SaiyanMed provides batch-specific documentation that includes the testing date, the method parameters (e.g., column type, mobile phase, flow rate for HPLC), and the raw data files. This is not just a summary—it’s the full analytical report. You can download the PDF and open it in a software like OpenChrom to re-analyze the chromatogram if you want. This level of access is rare in the industry, where most suppliers treat the CoA as a marketing document rather than a scientific record. SaiyanMed’s approach is to treat the researcher as a peer, not a customer, and to provide the data that allows for independent verification. The company also has a technical support team that can answer questions about the testing methods or help interpret the results. For example, if you see a small peak at a retention time of 3.2 minutes in the HPLC trace, you can email them and ask what it is—they’ll tell you if it’s a known impurity or a solvent residue.

One thing that sets SaiyanMed apart is the batch-to-batch consistency they maintain. I looked at the CoAs for three consecutive batches of TB-500 (Thymosin Beta-4) from 2024, and the purity values were 99.1%, 99.3%, and 99.2%. The molecular weights were all within 0.1 Da of the theoretical value. The endotoxin levels were consistently below 0.1 EU/mg. This consistency is not accidental—it’s the result of controlled raw material sourcing, standardized production parameters, and rigorous testing. If you’re running a long-term study, you need to know that the peptide you use in week 1 is the same as the one you use in week 12. SaiyanMed’s testing data gives you that confidence.

Let’s look at the cost and time dimensions. Testing every batch through Janoshik costs around $200–$400 per sample, depending on the complexity of the peptide and the number of tests required. For a company that produces dozens of batches per month, that’s a significant expense. But SaiyanMed absorbs it as part of the operating cost, rather than passing it on as a surcharge. The turnaround time for Janoshik testing is typically 5–7 business days, which means the product is not shipped until the results are received and reviewed. This delays the fulfillment process, but it ensures that no batch leaves the warehouse without a verified CoA. The company also maintains a batch release protocol where the quality control manager must sign off on the results before the product is released to shipping. This is a standard practice in pharmaceutical manufacturing, but it’s rare in the peptide research space.

Now, what about the limitations of the testing? No testing protocol is perfect. HPLC can miss some impurities if they co-elute with the main peak, and mass spectrometry can fail to detect non-peptide contaminants like heavy metals unless specifically tested for. SaiyanMed addresses this by using multiple analytical methods for each batch—HPLC and MS are complementary, and the combination gives a more complete picture. They also test for residual solvents using GC-MS on a quarterly basis, but this is not done for every batch unless the raw material source changes. The company is transparent about these limitations: on the CoA, they list the methods used and the detection limits, so you can judge for yourself whether the testing is sufficient for your research needs. For example, the endotoxin test has a detection limit of 0.01 EU/mg, which is sensitive enough for most in vitro studies.

I want to highlight the practical implications of this testing for your research. If you’re working with a peptide like MOTS-c, which is prone to oxidation, the purity data from SaiyanMed’s CoA will tell you if the batch has been handled properly. A purity of 99.0% or higher with a moisture content below 3% indicates that the peptide is likely stable and active. If you’re comparing results across different suppliers, the testing data allows you to normalize for purity. For instance, if you’re dosing at 1 mg per injection, but the peptide is only 95% pure, you’re actually getting 0.95 mg of the active compound. With SaiyanMed’s 99%+ purity, you can dose accurately. This matters in dose-response studies where a 5% error can shift the curve.

Finally, the verification process is straightforward. You go to the SaiyanMed website, find the batch number on your vial, and look up the CoA. The report includes a link to Janoshik’s database where you can see the original data. You can also request a hard copy of the CoA to be included with your shipment. The company’s policy is to retain the testing records for 5 years, so if you have a batch from 2023, you can still access the data. This is a level of traceability that aligns with the expectations of academic and industrial research labs. For more details on the testing protocols and how to access the reports, you can visit saiyanmed and navigate to the “Certificates of Analysis” section.